U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C10H8BrN5OS
Molecular Weight 326.172
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LOMEGUATRIB

SMILES

NC1=NC2=C(NC=N2)C(OCC3=CC(Br)=CS3)=N1

InChI

InChIKey=JUJPKFNFCWJBCX-UHFFFAOYSA-N
InChI=1S/C10H8BrN5OS/c11-5-1-6(18-3-5)2-17-9-7-8(14-4-13-7)15-10(12)16-9/h1,3-4H,2H2,(H3,12,13,14,15,16)

HIDE SMILES / InChI

Molecular Formula C10H8BrN5OS
Molecular Weight 326.172
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.astrazeneca.com/content/dam/az/our-company/investor-relations/presentations-and-webcast/Annual-Reports/2005-Annual_Report.pdf

Lomeguatrib is a O6-methylguanine-DNA-methyl-transferase inhibitor which was developed by AstraZeneca for the treatment of cancer. It was tested in phase I and II of clinical trials for the treatment of colorectal cancer, melanoma and other solid tumors.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P16455
Gene ID: 4255.0
Gene Symbol: MGMT
Target Organism: Homo sapiens (Human)
5.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
35.2 ng/mL
40 mg 1 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: TEMOZOLOMIDE
LOMEGUATRIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
104.4 ng × h/mL
40 mg 1 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: TEMOZOLOMIDE
LOMEGUATRIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.4 h
40 mg 1 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: TEMOZOLOMIDE
LOMEGUATRIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
2002 Aug 10
Quantitative trait locus analysis reveals two intragenic sites that influence O6-alkylguanine-DNA alkyltransferase activity in peripheral blood mononuclear cells.
2005 Aug
O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
2005 Nov 14
O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro.
2006 Apr
Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
2007 Aug 1
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
2009 Apr 21
Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib.
2010 Jan 15

Sample Use Guides

In Vivo Use Guide
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/16533784
In metastatic colorectal cancer: lomeguatrib (40 mg) is given together with temozolomide (50-200 mg m(-2)) orally for 5 consecutive days every 4 weeks. Advanced melanoma: lomeguatrib is given at dose of 40 mg, b.i.d. for 10 or 14 days and temozolomide 75-100 mg m(-2) on days 1-5. Drugs are administered orally with cycles repeated every 28 days, for up to six cycles. Advanced solid tumors: lomeguatrib is administered at dose levels of 10 to 40 mg/m2 (orally or intravenously) days 1 to 5, as a single agent, and also in combination with temozolomide.
Route of Administration: Other
Anaplastic astrocytoma cell lines were treated with a temozolomide-lomeguatrib combination at concentration of 50 uM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:07:56 GMT 2025
Edited
by admin
on Mon Mar 31 18:07:56 GMT 2025
Record UNII
S79265T71M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LOMEGUATRIB
INN   WHO-DD  
INN  
Official Name English
Lomeguatrib [WHO-DD]
Preferred Name English
lomeguatrib [INN]
Common Name English
O6-(4-Bromothenyl)guanine
Common Name English
6-((4-BROMO-2-THIENYL)METHOXYL)PURIN-2-AMINE
Systematic Name English
PaTrin-2
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2134
Created by admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL339133
Created by admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
PRIMARY
INN
8401
Created by admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
PRIMARY
EPA CompTox
DTXSID60172838
Created by admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
PRIMARY
EVMPD
SUB34828
Created by admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
PRIMARY
NCI_THESAURUS
C66028
Created by admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
PRIMARY
SMS_ID
100000128113
Created by admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
PRIMARY
PUBCHEM
3025944
Created by admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
PRIMARY
FDA UNII
S79265T71M
Created by admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
PRIMARY
MESH
C521206
Created by admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
PRIMARY
CAS
192441-08-0
Created by admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> ACTIVATOR
Potentiates theh activity of drugs that inhibit mismatched repair.
Related Record Type Details
ACTIVE MOIETY